Clinical trial
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and…
NCT03399370 · The Medicines Company, Industry · Completed
Key facts
| NCT number | NCT03399370 |
|---|---|
| Title | Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol |
| Official title | A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C) |
| Acronym | ORION-10 |
| Lead sponsor | The Medicines Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | ASCVD, Elevated Cholesterol |
| Intervention type | Drug |
| Interventions | Inclisiran Sodium, Placebo |
| Enrollment | 1,561 |
| Start date | Dec 21, 2017 |
| Primary completion | Sep 10, 2019 |
| Completion | Sep 17, 2019 |
| First posted | Jan 16, 2018 |
| Last update posted | Oct 5, 2020 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: